These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32793911)

  • 1. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Sheltzer JM; Kjolby M; Pöhlmann S
    bioRxiv; 2020 Aug; ():. PubMed ID: 32793911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
    Breining P; Frølund AL; Højen JF; Gunst JD; Staerke NB; Saedder E; Cases-Thomas M; Little P; Nielsen LP; Søgaard OS; Kjolby M
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):204-212. PubMed ID: 33176395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
    Kitagawa J; Arai H; Iida H; Mukai J; Furukawa K; Ohtsu S; Nakade S; Hikima T; Haranaka M; Uemura N
    Clin Transl Sci; 2021 Sep; 14(5):1967-1976. PubMed ID: 33982445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    bioRxiv; 2021 Aug; ():. PubMed ID: 34100014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
    Shirato K; Kawase M; Matsuyama S
    J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
    Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease inhibitors targeting coronavirus and filovirus entry.
    Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
    Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2.
    Escalante DE; Ferguson DM
    Med Chem Res; 2021; 30(2):399-409. PubMed ID: 33564221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
    Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.
    Azouz NP; Klingler AM; Callahan V; Akhrymuk IV; Elez K; Raich L; Henry BM; Benoit JL; Benoit SW; Noé F; Kehn-Hall K; Rothenberg ME
    Pathog Immun; 2021; 6(1):55-74. PubMed ID: 33969249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.